Director Declaration
In brief · summary, not quotable
No summary for this filing – the full text is below.
Full announcement
Select text to share a quote on X · sign in to keep highlights & notes in your OXB notes
Oxford, UK - 30 July 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, announces that Dr. Frank Mathias, Chief Executive Officer, has been appointed as Chairman of the Board of Directors of ArcticZymes Technologies ASA.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.